CN102573890A - 经过修饰的因子ix多肽及其用途 - Google Patents

经过修饰的因子ix多肽及其用途 Download PDF

Info

Publication number
CN102573890A
CN102573890A CN2010800431356A CN201080043135A CN102573890A CN 102573890 A CN102573890 A CN 102573890A CN 2010800431356 A CN2010800431356 A CN 2010800431356A CN 201080043135 A CN201080043135 A CN 201080043135A CN 102573890 A CN102573890 A CN 102573890A
Authority
CN
China
Prior art keywords
fix
polypeptide
amino acid
gather
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800431356A
Other languages
English (en)
Chinese (zh)
Inventor
A.布鲁克斯
C.帕特尔
蒋晓乔
U.格里赞
H.阿佩勒
王俊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102573890(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of CN102573890A publication Critical patent/CN102573890A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2010800431356A 2009-07-31 2010-08-02 经过修饰的因子ix多肽及其用途 Pending CN102573890A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23055109P 2009-07-31 2009-07-31
US61/230,551 2009-07-31
PCT/US2010/044177 WO2011014890A1 (en) 2009-07-31 2010-08-02 Modified factor ix polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
CN102573890A true CN102573890A (zh) 2012-07-11

Family

ID=43529743

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800431356A Pending CN102573890A (zh) 2009-07-31 2010-08-02 经过修饰的因子ix多肽及其用途

Country Status (21)

Country Link
US (1) US20120164130A1 (https=)
EP (1) EP2461821A4 (https=)
JP (1) JP2013500726A (https=)
KR (1) KR20120060209A (https=)
CN (1) CN102573890A (https=)
AU (1) AU2010278721A1 (https=)
BR (1) BR112012002072A2 (https=)
CA (1) CA2769258A1 (https=)
CL (1) CL2012000238A1 (https=)
CR (1) CR20120052A (https=)
CU (3) CU20120018A7 (https=)
DO (1) DOP2012000030A (https=)
EA (1) EA201290069A1 (https=)
EC (1) ECSP12011637A (https=)
GT (1) GT201200023A (https=)
IN (1) IN2012DN00908A (https=)
MX (1) MX2012001346A (https=)
PE (1) PE20121643A1 (https=)
SG (1) SG178119A1 (https=)
WO (1) WO2011014890A1 (https=)
ZA (1) ZA201200716B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105451774A (zh) * 2013-04-28 2016-03-30 拜耳医药保健有限公司 用于诱导对凝固因子蛋白的免疫耐受的组合物

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2670618C (en) 2006-12-15 2016-10-04 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
EP4219547A3 (en) 2008-09-15 2023-10-18 uniQure biopharma B.V. Factor ix polypeptide mutant, its uses and a method for its production
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CN102497884A (zh) 2009-07-27 2012-06-13 巴克斯特国际公司 凝血蛋白缀合物
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
KR101912335B1 (ko) 2009-07-27 2018-10-26 리폭센 테크놀로지즈 리미티드 비혈액 응고 단백질의 글리코폴리시알화
CN106110311A (zh) 2009-07-27 2016-11-16 百深公司 凝血蛋白缀合物
DK2598172T3 (da) * 2010-07-30 2019-07-01 Baxalta GmbH Nukleofile katalysatorer til oximforbindelse
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
CN104144950B (zh) * 2011-12-19 2017-09-05 迪乐方有限责任公司 含有重复的二糖单元的非抗凝的葡糖胺聚糖及其医药用途
BR112015011462A2 (pt) * 2012-11-20 2017-09-26 Univ North Carolina Chapel Hill processos e composições para proteínas fator ix modificadas
AU2014248617B2 (en) * 2013-03-13 2016-05-19 Ambrx, Inc. Modified canine leptin polypeptides
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
CA3034566A1 (en) 2016-07-27 2018-02-01 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
JP7578590B2 (ja) 2018-10-18 2024-11-06 インテリア セラピューティクス，インコーポレーテッド 第ｉｘ因子を発現するための組成物及び方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1520259A (zh) * 2001-04-25 2004-08-11 ���ݴ�ѧУ��ίԱ�� 利用球状载体将第八因子/第九因子进行肝脏基因转移治疗血友病的方法
US20080102115A1 (en) * 2006-06-19 2008-05-01 Jorge Oyhenart Modified coagulation factor IX polypeptides and use thereof for treatment
US20080167219A1 (en) * 2007-01-09 2008-07-10 Shu-Wha Lin Recombinant human factor ix and use thereof
US20090081188A1 (en) * 2003-12-03 2009-03-26 Neose Technologies, Inc. Glycopegylated factor ix

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004296860B2 (en) * 2003-12-03 2010-04-22 Novo Nordisk A/S Glycopegylated factor IX

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1520259A (zh) * 2001-04-25 2004-08-11 ���ݴ�ѧУ��ίԱ�� 利用球状载体将第八因子/第九因子进行肝脏基因转移治疗血友病的方法
US20090081188A1 (en) * 2003-12-03 2009-03-26 Neose Technologies, Inc. Glycopegylated factor ix
US20080102115A1 (en) * 2006-06-19 2008-05-01 Jorge Oyhenart Modified coagulation factor IX polypeptides and use thereof for treatment
US20080167219A1 (en) * 2007-01-09 2008-07-10 Shu-Wha Lin Recombinant human factor ix and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHUETTRUMPF J等: "Factor IX variants improve gene therapy efficacy for hemophilia B", 《BLOOD》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105451774A (zh) * 2013-04-28 2016-03-30 拜耳医药保健有限公司 用于诱导对凝固因子蛋白的免疫耐受的组合物

Also Published As

Publication number Publication date
AU2010278721A1 (en) 2012-02-16
WO2011014890A1 (en) 2011-02-03
EP2461821A1 (en) 2012-06-13
CR20120052A (es) 2012-06-04
ZA201200716B (en) 2013-07-31
SG178119A1 (en) 2012-03-29
PE20121643A1 (es) 2012-11-25
KR20120060209A (ko) 2012-06-11
BR112012002072A2 (pt) 2016-11-08
CU20130057A7 (es) 2013-06-28
CU20120018A7 (es) 2012-06-21
IN2012DN00908A (https=) 2015-04-03
MX2012001346A (es) 2012-02-17
DOP2012000030A (es) 2012-02-29
CL2012000238A1 (es) 2012-10-05
CA2769258A1 (en) 2011-02-03
CU20130058A7 (es) 2013-06-28
ECSP12011637A (es) 2012-02-29
EP2461821A4 (en) 2013-07-03
JP2013500726A (ja) 2013-01-10
EA201290069A1 (ru) 2012-07-30
GT201200023A (es) 2014-01-27
US20120164130A1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
US20120164130A1 (en) Modified Factor IX Polypeptides and Uses Thereof
CA2721362A1 (en) Site-directed modification of factor ix
KR102068133B1 (ko) 혈액 응고 단백질 복합체
JP5876208B2 (ja) 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体
JP2022171790A (ja) 第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法
US20090252720A1 (en) Prolonged FIX Analogues and Derivatives
ES2731626T3 (es) Catalizadores nucleofílicos para enlace oxima
CN102083856A (zh) 经修饰的因子ix多肽及其用途
CA2571292A1 (en) Polymer-factor ix moiety conjugates
KR102326360B1 (ko) 옥심 결합을 위한 친핵성 촉매
TW201247709A (en) Therapeutic proteins with increased half-life and methods of preparing same
JP2018035192A (ja) 血液凝固タンパク質複合体
HK1172840A (en) Modified factor ix polypeptides and uses thereof
HK1153383A (zh) 因子ix的定點修飾

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1172840

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120711

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1172840

Country of ref document: HK